7 Signs of Carcinoid Syndrome That Should Not Be Ignored

Carcinoid syndrome is a group of symptoms that can occur when certain neuroendocrine tumors release excessive amounts of hormones and other chemicals into the bloodstream. These tumors, known as carcinoid tumors, often develop in the digestive tract or lungs and may grow slowly over time. Many people with these tumors do not experience symptoms at first, but when the released substances affect other parts of the body, carcinoid syndrome can develop.

Recognizing the signs of carcinoid syndrome is important because the symptoms may be mistaken for other common conditions. Warning signs can include sudden facial flushing, diarrhea, wheezing, rapid heartbeat, abdominal discomfort, and changes in heart valve function. These symptoms may come and go at first but can become more frequent as hormone levels increase. This article explains seven signs of carcinoid syndrome that should not be ignored, along with possible causes, diagnosis methods, and treatment options.

What exactly is Carcinoid Syndrome?

Carcinoid syndrome is a rare paraneoplastic condition that occurs when an advanced neuroendocrine tumor (NET) secretes excessive amounts of vasoactive hormones and chemicals directly into the systemic bloodstream. It is not a distinct form of cancer itself, but rather the clinical impact caused by the hormonal activity of an underlying carcinoid tumor.

The Biological Mechanisms Underlying Carcinoid Syndrome

To understand this condition, it helps to look at how these tumors interact with the body’s natural filtration systems.

Neuroendocrine tumors most commonly originate in the gastrointestinal tract (such as the small intestine or appendix). Under normal conditions, any hormones secreted by a tumor localized in the gut travel directly through the portal vein into the liver. The liver utilizes specific enzymes, such as monoamine oxidase, to metabolize and completely inactivate these substances before they can reach the rest of the body. This protective process is known as first-pass metabolism, and it explains why the majority of patients with early-stage tumors remain completely asymptomatic.

Carcinoid syndrome typically develops only after the cancer has metastasized (spread) to the liver. Once tumor deposits are physically established within the liver tissue, they release their chemical products directly into the hepatic veins. These veins empty straight into the inferior vena cava and the general circulation. By bypassing the liver’s primary metabolic filtration system, these active hormones are free to travel throughout the body, interacting with various tissue receptors to produce a complex array of systemic effects.

Recognizing Carcinoid Syndrome Symptoms

The physiological changes triggered by these circulating chemicals create a very distinct clinical pattern. Patients typically experience a multi-system cluster of carcinoid syndrome symptoms that affect the skin, gastrointestinal tract, and respiratory system simultaneously:

Cutaneous Flushing: This is often the most common and earliest sign. It presents as a sudden, intense reddening of the skin—typically localized to the face, neck, and upper chest—accompanied by a distinct sensation of heat. Unlike standard blushing, these episodes are triggered chemically by substances like histamine and bradykinin and can be brought on by eating certain foods, drinking alcohol, or experiencing emotional stress.

Gastrointestinal Distress: The massive overproduction of serotonin heavily stimulates the motility of the gut. This results in chronic, severe, and watery diarrhea that is frequently accompanied by abdominal cramping, urgency, and bloating. Notably, this diarrhea can happen at any time, often waking patients up in the middle of the night.

Bronchoconstriction: The release of tachykinins and prostaglandins can cause the smooth muscles in the airways to tighten. This causes asthma-like carcinoid syndrome symptoms such as wheezing, coughing, and sudden shortness of breath.

Systemic Deficiencies (Pellagra): Because the tumor diverts huge amounts of the essential amino acid tryptophan to manufacture serotonin, the rest of the body can run out of the nutrients needed to make vitamin B3. This can lead to niacin deficiency (pellagra), which causes rough skin, tongue swelling, and mental confusion.

Diagnostic Distinctions and When to Seek Care

Neuroendocrine tumors are broadly categorized as either functional or non-functional. Non-functional tumors do not secrete active hormones, meaning patients only experience localized symptoms like physical pain or a bowel obstruction caused by the physical size of the mass. Functional tumors, on the other hand, actively manufacture and release chemicals, making carcinoid syndrome the clinical hallmark of a functional neuroendocrine tumor.

Because individual carcinoid syndrome symptoms like diarrhea or flushing are common on their own and easily mistaken for regular conditions like Irritable Bowel Syndrome (IBS), rosacea, or standard asthma, it is vital to evaluate them as a combined pattern.

If you or a loved one experience a persistent combination of unexplained skin flushing and chronic watery diarrhea, it is important to seek a detailed medical workup. Early screening—such as a 24-hour urine test checking for 5-HIAA (a major byproduct of serotonin breakdown) or advanced imaging like a Ga-68 DOTATATE PET/CT scan—is the crucial first step toward identifying the underlying neuroendocrine tumor and beginning targeted, effective treatment.

7 Warning Signs of Carcinoid Syndrome

The 7 primary warning signs of Carcinoid Syndrome are cutaneous flushing, severe diarrhea, abdominal pain, carcinoid heart disease, asthmatic-like wheezing, telangiectasias, and peripheral edema, all caused by excessive hormone secretion from neuroendocrine tumors.

Cutaneous Flushing: The Early Vascular Warning Sign

Cutaneous flushing is the classic clinical hallmark and often the earliest recognizable warning sign of carcinoid syndrome. It is experienced by up to 85% of individuals with functional neuroendocrine tumors. This phenomenon is distinctly different from ordinary emotional blushing or the gradual flushing associated with menopause; it is a profound, biochemically mediated vascular event.

When a functional neuroendocrine tumor releases potent vasoactive chemicals—specifically bradykinin, histamine, prostaglandins, and tachykinins—directly into the systemic circulation, these substances bind to receptors on the smooth muscle walls of peripheral blood vessels. This triggers sudden, widespread dilation of the tiny capillaries located just beneath the skin’s surface.

Clinical Presentation: The flush typically manifests as a sudden, intense reddening or deep violaceous (purplish) discoloration of the skin. It is overwhelmingly localized to the “flush components” of the upper body, which include the face, neck, and upper chest.

Sensory Experience: The visible color change is accompanied by a physical sensation of intense, uncomfortable heat, skin tightness, and occasionally a transient rise in local skin temperature.

Duration and Timeline: In its early stages, flushing is highly episodic, with individual attacks lasting anywhere from 2 to 30 minutes. The frequency can range from multiple episodes a day to a few isolated occurrences a month. Over several years, if left untreated, the flushing can become prolonged, lasting for hours, and may eventually transition into a permanent, dusky, cyanotic skin tone due to chronic vascular stagnation.

Dietary and Emotional Triggers: These episodes can happen spontaneously, but they are frequently brought on by distinct, identifiable triggers. Consumption of alcohol—particularly red wine—is a notorious precipitant, as it prompts the rapid release of catecholamines that stimulate the tumor to dump its hormonal stores. Similarly, eating foods rich in tyramine (such as aged cheeses, cured meats, chocolate, and fermented items), physical exertion, or sudden emotional stress can immediately initiate a severe flushing episode.

Severe, Watery Diarrhea: Serotonin-Driven Dysmotility

Severe diarrhea represents one of the most physically exhausting and debilitating carcinoid syndrome symptoms. This symptom is primarily driven by the tumor’s massive, unchecked synthesis and secretion of serotonin (5-hydroxytryptamine or 5-HT) into the systemic circulation.

Serotonin is a powerful signaling molecule within the gastrointestinal tract’s enteric nervous system. While normal physiological levels of serotonin help coordinate healthy digestion, the excessive volumes produced in carcinoid syndrome throw the entire digestive system into severe malfunction via two distinct pathways:

Gastrointestinal Hypermotility: Excess circulating serotonin binds to 5-HT3 and 5-HT4 receptors on the smooth muscles lining the intestines. This overstimulates the muscles, causing them to contract with excessive frequency and force. This hypermotility accelerates peristalsis, rushing digesting food and waste through the small and large intestines far too quickly for the mucosal lining to properly absorb vital nutrients, fats, and water.

Secretory Diarrhea Dynamics: Concurrently, serotonin acts directly on the enterocytes (the epithelial cells lining the inside of the intestines), prompting them to actively secrete large volumes of water, chloride, and potassium into the intestinal lumen. This combination of accelerated transit and massive fluid dumping produces a classic secretory diarrhea.

Clinical Distinctions: The resulting stools are characteristically voluminous, watery, and urgent. Unlike osmotic diarrhea (which improves when a person fasts), secretory carcinoid diarrhea persists independently of food intake. It frequently occurs 5 to 20+ times per day and routinely wakes patients from a deep sleep (nocturnal diarrhea). Over time, this chronic fluid loss causes severe dehydration, profound electrolyte imbalances (hypokalemia), steatorrhea (unabsorbed fat in the stool), and rapid, unintentional weight loss.

Cramping Abdominal Pain: Smooth Muscle Spasms and Fibrosis

Abdominal pain is a frequent warning sign that presents with varying degrees of severity, often changing as the underlying neuroendocrine tumor advances. This symptom is rarely localized to a single spot; instead, it is driven by a combination of hormonal muscle stimulation and structural changes inside the abdominal cavity:

Hypermotility and Muscle Spasms: The mildest and most common form of abdominal pain is an episodic, cramping, or “colicky” discomfort that directly mirrors the waves of severe diarrhea. As excessive serotonin forces the smooth muscles of the bowel into powerful, uncoordinated, and spasmodic contractions, the patient experiences griping pains. These pains typically intensify just before an urgent bowel movement and may briefly subside afterward.

Tumor Mass Effects: As the cancer spreads, the physical bulk of the tumors can cause a deep, constant ache. Because carcinoid tumors often metastasize heavily to the liver, the growing tumor deposits can stretch Glisson’s capsule—the protective, nerve-rich layer of connective tissue enclosing the liver. This stretching results in a constant, heavy, dull ache localized to the right upper quadrant of the abdomen.

Mesenteric Fibrosis (Desmoplasia): The most severe and hazardous cause of abdominal pain in carcinoid syndrome is a structural complication known as mesenteric fibrosis. The high concentrations of serotonin and tachykinins pooling in the local tissues stimulate a powerful fibroblastic response, causing the body to produce dense, thick bands of scar tissue within the mesentery (the membrane that anchors the intestines to the abdominal wall). This scar tissue can contract over time, physically kinking or twisting loops of the bowel, which can lead to a partial or complete bowel obstruction. This blockage causes severe, wave-like abdominal pain, nausea, and vomiting. If the fibrous bands constrict the mesenteric blood vessels, they can cut off blood flow to the gut (intestinal ischemia), causing constant, agonizing pain that constitutes a life-threatening surgical emergency.

Carcinoid Heart Disease: Right-Sided Endocardial Plaque Build-Up

Carcinoid heart disease is a unique structural complication that develops in up to 50% of patients with long-standing carcinoid syndrome. This condition is a direct result of the heart being constantly exposed to high levels of circulating serotonin and other tumor-secreted chemicals.

The Right-Side Bias: This pathology almost exclusively damages the right side of the heart—specifically the tricuspid and pulmonary valves. This happens because the vasoactive hormones are dumped by liver metastases directly into the hepatic veins, traveling straight into the inferior vena cava and into the right atrium and ventricle. When this hormone-rich blood is pumped out of the right ventricle and into the lungs, the lung tissue utilizes specific enzymes (primarily monoamine oxidase) to completely break down and inactivate the excess serotonin. Because the blood is thoroughly filtered by the lungs before looping back to the left side of the heart, the left atrium, left ventricle, mitral valve, and aortic valve are typically spared from damage.

Pathological Mechanism: Persistently elevated serotonin levels stimulate 5-HT2B receptors on the endocardial surface, triggering a massive overgrowth of smooth muscle cells and extracellular matrix components. This forms dense, pearly-white, fibrous plaques on the endocardium and the valve leaflets.

Structural Valve Damage: These fibrous plaques cause the delicate leaflets of the tricuspid and pulmonary valves to become thickened, rigid, and retracted. The valves lose their flexibility and can no longer open or close properly. This results in a severe combination of valve stenosis (narrowing of the opening, which blocks blood from pumping forward) and valve regurgitation (leaking of the valve, which allows blood to flow backward).

Progression to Heart Failure: This structural damage forces the right ventricle to work exponentially harder to pump blood through the stiffened pulmonary valve, while simultaneously dealing with blood leaking backward through the tricuspid valve. Over time, the right ventricle stretches, weakens, and eventually fails. Clinical signs of this cardiac decline include progressive shortness of breath (dyspnea) during light exertion, profound fatigue, a distinct cardiac murmur during examination, and significant fluid retention.

Asthmatic-Like Wheezing: Hormonal Airway Constriction

Respiratory issues in carcinoid syndrome present as sudden, frightening episodes of shortness of breath accompanied by a high-pitched, whistling sound during exhalation. While these carcinoid syndrome symptoms appear identical to a classic asthma attack, the underlying biological mechanism is entirely different. This respiratory distress can develop in individuals with no prior history of reactive airway disease or allergies.

• Chemical Bronchoconstriction: Instead of being driven by an allergic immune response or environmental allergens, this airway narrowing is caused by tumor-secreted chemicals—primarily bradykinin and prostaglandins, with serotonin playing a supporting role. When these substances reach the pulmonary capillaries, they cause the smooth muscle bands wrapped around the bronchioles to spasm and tightly constrict, narrowing the path for airflow.

• Clinical Presentation: These wheezing attacks are highly episodic and frequently occur at the exact same time as a cutaneous flushing episode, as both symptoms are triggered by the same sudden surge of tumor hormones into the bloodstream. An attack can be brought on by the same triggers that cause flushing, such as alcohol consumption or emotional stress.

• Treatment Failure as a Clue: A critical diagnostic clue for physicians is that this hormonal wheezing often fails to respond effectively to standard asthma medications, such as short-acting beta-agonist rescue inhalers (e.g., albuterol). Because the underlying cause is not an inflammatory or adrenergic issue but a direct hormonal overstimulation of the airway muscles, managing the symptom requires systemic therapies (like somatostatin analogs) that stop the neuroendocrine tumor from releasing hormones in the first place.

Telangiectasias: Chronic, Permanent Vascular Damage

While cutaneous flushing is a temporary, episodic warning sign, telangiectasias represent a long-term, structural manifestation of carcinoid syndrome on the patient’s skin.

Vascular Exhaustion: Telangiectasias are small, permanently dilated capillaries and venules located just beneath the skin’s surface. They look like fine, thread-like red, blue, or purplish lines arranged in a web-like pattern. They develop as a direct consequence of years of repeated, severe flushing episodes. During every flush, the tiny blood vessels in the face are forced to expand to their absolute maximum capacity. Over years of repeated episodes, the elastic fibers within the delicate walls of these tiny vessels wear out and lose their ability to snap back to their normal size. The vessels remain permanently stretched open, filled with blood even when the patient is not actively flushing.

Anatomical Distribution: Because they are caused by flushing, they form in the exact same areas where flushing is most severe: across the bridge of the nose, the upper lip, the apples of the cheeks, and occasionally the neck.

Clinical Significance: The presence of extensive telangiectasias is a strong visual indicator of long-standing, poorly controlled carcinoid syndrome. These markings are completely flat, do not cause itching or pain, and will momentarily blanch (turn white) when physical pressure is applied before rapidly refilling with blood once the pressure is released. Because they look similar to the vascular changes caused by rosacea or chronic sun damage, evaluating them alongside other system-wide symptoms is vital for an accurate diagnosis.

 Peripheral Edema: Multifactorial Fluid Accumulation

Peripheral edema—manifesting as visible, bilateral swelling in the feet, ankles, and lower legs—is an advanced warning sign of carcinoid syndrome. This fluid retention is rarely caused by a single issue; rather, it is a multi-system complication that points to advanced disease progression through three distinct pathways:

Right-Sided Heart Failure Backup: The primary and most common driver of peripheral edema is advanced carcinoid heart disease. As the tricuspid and pulmonary valves stiffen and leak, the weakened right ventricle can no longer pump blood forward efficiently. As a result, blood backs up into the large veins of the body, causing increased pressure within the venous system. Gravity causes this excess pressure to build up in the lowest parts of the body. This pressure forces the watery components of the blood to leak through the capillary walls and pool in the surrounding tissues of the lower legs and feet. This swelling is typically “pitting,” meaning that if you press a finger into the swollen area for a few seconds, a temporary indentation remains after you lift your finger.

Hypoalbuminemia from Gut Malabsorption: Chronic, severe secretory diarrhea can cause substantial protein loss through the damaged gastrointestinal tract, while hypermotility prevents the proper absorption of dietary proteins. This leads to abnormally low levels of albumin in the bloodstream (hypoalbuminemia). Albumin is a crucial protein responsible for maintaining oncotic pressure—the biological force that holds water inside the blood vessels. When albumin levels drop significantly, this holding force weakens, allowing fluid to leak freely into the body’s tissues and worsening the swelling in the legs.

Liver Dysfunction: While the liver can continue to function well despite extensive metastasis, a massive tumor burden within the organ can eventually impair its ability to manufacture albumin, further worsening the drop in blood proteins and intensifying the physical swelling.

How is Carcinoid Syndrome diagnosed and differentiated from other conditions?

The process of diagnosing carcinoid syndrome requires a coordinated, two-step medical investigation. First, clinical teams must biochemically prove that the body is being flooded with excessive tumor-secreted hormones. Second, advanced functional imaging must be deployed to map out exactly where the primary neuroendocrine tumor and its metastases are located.

Because individual carcinoid syndrome symptoms closely mirror much more common ailments, this clear diagnostic roadmap prevents misdiagnosis and directs appropriate, target-specific therapy.

1. The Diagnostic Protocol

Biochemical Testing (Proving Hormone Excess)

• 24-Hour Urine 5-HIAA: This remains the primary biochemical test. It measures 5-hydroxyindoleacetic acid (5-HIAA), which is the main waste product created when the liver breaks down excess serotonin. Because certain foods can artificially spike serotonin levels and skew the results, patients must strictly avoid items like bananas, avocados, walnuts, pineapples, and plums for 3 days before and during the urine collection.

• Serum Chromogranin A (CgA): This blood test measures a specific protein found inside neuroendocrine cells. While highly sensitive for tracking tumor volume, CgA is not completely specific to carcinoid syndrome. It can be elevated by unrelated issues, such as renal insufficiency, or by taking common acid-reflux medications like proton pump inhibitors (PPIs).

Advanced Functional Imaging (Locating the Tumor)

Once hormone excess is proven, clinicians move past standard CT or MRI scans to utilize targeted nuclear medicine. Neuroendocrine tumors heavily express specific docking ports called somatostatin receptors on their outer cell surfaces. Modern imaging exploits this biology:

• Ga-68 DOTATATE PET/CT: This scan injects a radioactive tracer that binds tightly to these somatostatin receptors, causing even microscopic tumor deposits to “light up” brilliantly on the screen. It has largely replaced the older, less sensitive OctreoScan due to its exceptional resolution.

• Tissue Biopsy: Ultimately, extracting a small physical sample of the mass provides the definitive diagnosis, allowing pathologists to confirm the neuroendocrine nature of the cells under a microscope.

Explaining the Difference: Tumor vs. Syndrome

It is a common point of confusion, but a carcinoid tumor and carcinoid syndrome are not the same thing:

• The Carcinoid Tumor (The Mass): This is the actual physical cancer. It is a slow-growing malignancy that arises from neuroendocrine cells, most frequently located deep within the small intestine, appendix, or lungs.

• Carcinoid Syndrome (The Systemic Effect): This is the collection of symptoms (flushing, diarrhea, wheezing) caused when a tumor actively manufactures and dumps active chemicals into the systemic circulation.

Fewer than 10% of patients with a carcinoid tumor ever develop the syndrome. This is because a tumor confined to the gut has its hormones immediately destroyed by the liver’s “first-pass” metabolism. The syndrome almost exclusively emerges only after the tumor has spread (metastasized) to the liver, allowing the tumor cells to dump hormones straight into the hepatic veins, completely bypassing the liver’s protective filtration system.

Differential Diagnosis: Avoiding Common Blunders

Because the symptoms of this condition are non-specific and episodic, patients are frequently misdiagnosed for years with common diseases. Clinicians look for specific clues to differentiate them:

Misdiagnosis	Overlapping Symptom	The Carcinoid Syndrome Distinction
Irritable Bowel Syndrome (IBS)	Chronic diarrhea & abdominal cramping.	Carcinoid diarrhea is secretory—it is watery, high-volume, fails to improve with fasting, and uniquely wakes the patient up in the middle of the night (nocturnal diarrhea).
Rosacea / Menopausal Hot Flashes	Episodic facial flushing & warmth.	Carcinoid flushing is systemic (spreading to the neck and chest), can take on a distinct purplish/violaceous tint, and is triggered by specific chemical catalysts like alcohol or tyramine-rich foods.
Adult-Onset Asthma	Wheezing & shortness of breath.	Carcinoid bronchoconstriction occurs as a distinct cluster simultaneously alongside flushing episodes. It is driven by bradykinin, meaning it typically fails to respond to standard rescue inhalers like albuterol.

The Ultimate Danger: Carcinoid Crisis

A carcinoid crisis is an acute, life-threatening escalation of carcinoid syndrome symptoms that constitutes a severe medical emergency. It occurs when the tumor suddenly and massively “degranulates,” dumping an overwhelming wave of vasoactive substances into the bloodstream all at once.

• The Presentation: A crisis causes profound, prolonged body-wide flushing, intense airway constriction (severe bronchospasm) that makes breathing nearly impossible, rapid heart arrhythmias, and a dangerous, precipitous drop in blood pressure (profound hypotension) leading to cardiovascular collapse or shock.

• The Triggers: This event is rarely spontaneous. It is almost always triggered by physical or chemical stress applied directly to the tumor cells—such as physical manipulation during surgery, a needle biopsy, the induction of general anesthesia, or starting liver-directed tumor therapies (like embolization).

• Prevention: To prevent a crisis from occurring, any patient with known or suspected carcinoid syndrome is pre-treated with a continuous intravenous infusion of a somatostatin analog, such as octreotide, prior to undergoing any surgical, diagnostic, or invasive medical procedure.

Conclusion

Carcinoid syndrome is a condition that requires medical evaluation because its symptoms may indicate an underlying neuroendocrine tumor. Flushing, persistent diarrhea, breathing problems, heart-related symptoms, and unexplained changes in health should not be overlooked, especially when they occur repeatedly or without an obvious cause. Treatment depends on the location and stage of the tumor and may include medications to control hormone release, surgery, targeted therapies, or other cancer treatments. Early diagnosis and ongoing monitoring can help manage symptoms, reduce complications, and improve quality of life.

Read more: NUT Carcinoma: Symptoms, Causes, Diagnosis, and Treatment Options

Frequently Asked Questions

1. What is carcinoid syndrome?

Carcinoid syndrome occurs when neuroendocrine tumors release excessive amounts of substances such as serotonin and other hormones into the bloodstream. These chemicals can affect different organs and cause symptoms involving the skin, digestive system, lungs, and heart. Not everyone with a carcinoid tumor develops this syndrome. It is more likely to occur when tumors have spread or release larger amounts of hormone-like substances.

2. What are the common signs of carcinoid syndrome?

Common symptoms of carcinoid syndrome include facial flushing, frequent diarrhea, wheezing, abdominal cramps, rapid heartbeat, and unexplained fatigue. Some people may also develop heart valve problems caused by long-term exposure to high serotonin levels. Symptoms can appear suddenly and may be triggered by certain foods, alcohol, stress, or medications. Repeated episodes should be evaluated by a healthcare provider.

3. What causes carcinoid syndrome?

Carcinoid syndrome is caused by neuroendocrine tumors that release excess hormones and chemicals into the body. These tumors most commonly develop in the gastrointestinal tract, including the small intestine, appendix, and rectum, or in the lungs. The syndrome often occurs when tumor cells have spread to the liver, allowing hormones to enter the bloodstream more easily. The exact symptoms depend on the substances released and where the tumor is located.

4. How is carcinoid syndrome diagnosed?

Doctors diagnose carcinoid syndrome through a combination of symptom evaluation, blood tests, urine tests, and imaging studies. A common test measures levels of 5-hydroxyindoleacetic acid (5-HIAA), a breakdown product of serotonin found in urine. Imaging tests such as CT scans, MRI, or specialized nuclear medicine scans may help locate neuroendocrine tumors. Additional tests may be used to assess whether the disease has spread.

5. How is carcinoid syndrome treated?

Treatment for carcinoid syndrome focuses on controlling symptoms and treating the underlying neuroendocrine tumor. Medications called somatostatin analogs, such as octreotide or lanreotide, can help reduce hormone release and improve symptoms. Surgery may be an option when tumors can be removed, while other treatments may include targeted therapy, radiation-based treatments, or chemotherapy. The treatment plan depends on tumor location, size, and spread.

6. Can carcinoid syndrome cause heart problems?

Yes. Long-term carcinoid syndrome can affect the heart, particularly the valves on the right side of the heart. Excess serotonin and related chemicals can cause scar-like changes that interfere with normal valve function, leading to a condition called carcinoid heart disease. Symptoms may include shortness of breath, swelling in the legs, fatigue, and reduced exercise ability. Regular heart monitoring may be recommended for people with ongoing carcinoid syndrome.

7. When should someone see a doctor about possible carcinoid syndrome?

A person should seek medical advice if they experience repeated episodes of unexplained flushing, chronic diarrhea, wheezing, rapid heartbeat, or other unusual symptoms. These signs do not always mean carcinoid syndrome, but persistent symptoms should be investigated to identify the underlying cause. People with a known neuroendocrine tumor should report new or worsening symptoms to their healthcare team. Early evaluation can help with diagnosis and symptom management.

Sources

Mayo Clinic. Carcinoid Syndrome.
Cleveland Clinic. Carcinoid Syndrome. 
National Cancer Institute. Gastrointestinal Neuroendocrine Tumors. 
American Cancer Society. Gastrointestinal Carcinoid Tumor. 
National Organization for Rare Disorders. Carcinoid Syndrome. 
National Institute of Diabetes and Digestive and Kidney Diseases. Neuroendocrine Tumors. 
American Society of Clinical Oncology. Neuroendocrine Tumors: Symptoms and Treatment.